Welcome to our dedicated page for CERUS SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERUS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERUS's regulatory disclosures and financial reporting.
Cerus Corporation, developer of the INTERCEPT Blood System, reported higher product revenue while remaining loss-making for the quarter ended June 30, 2026. Product revenue was $57,441 (in thousands), up from $52,445 (in thousands) a year earlier, with additional government contract revenue of $5,862 (in thousands).
Loss from operations narrowed to $1,858 (in thousands), and net loss attributable to Cerus was $2,940 (in thousands), or $0.01 per basic and diluted share, compared with $0.03 a year earlier. Cash and cash equivalents were $17,980 (in thousands) and short-term investments $38,284 (in thousands). Total debt principal was $65,088 (in thousands), comprising a $35,000 (in thousands) term loan at an interest rate of approximately 9.4% and $30,088 (in thousands) outstanding under a revolving credit facility. Cerus also highlighted substantial non-dilutive funding capacity through BARDA and DoD contracts supporting red blood cell and cryoprecipitate programs.
Cerus Corporation reported Q2 2026 total revenue of $63.3 million, up 5% year over year, with product revenue of $57.4 million growing 10% and broad-based strength across product categories. INTERCEPT Fibrinogen Complex demand rose about 20%, and U.S. IFC sales reached $6.7 million versus $5.6 million.
Product gross profit was $29.5 million, though product gross margin declined to 51.4% from 55.2% due to currency and higher costs. Operating expenses fell 7% to $37.3 million, helping narrow net loss attributable to Cerus to $2.9 million, or $0.01 per share, while non-GAAP adjusted EBITDA improved to a positive $3.0 million.
Cash, cash equivalents and short-term investments totaled $56.3 million, with $35.0 million outstanding on the term loan and $30.1 million drawn on the revolver after a refinancing that reduced the term loan by $30 million. A BARDA contract expansion added $21.9 million of potential value to support INTERCEPT Red Blood Cell development. Management raised 2026 product revenue guidance to $229–$231 million, including higher IFC guidance of $23–$25 million, implying 11–12% and roughly 40–50% growth from 2025.
Cerus Corp reported that Chief Executive Officer Vivek K. Jayaraman completed a sale of 16666 shares of Common Stock on July 16, 2026 at $3.16 per share. The sale was executed pursuant to a 10b5-1 trading plan, and he now directly holds 2232211 shares.
Vivek K. Jayaraman has given notice of intention to sell up to 16,666 shares of CERS common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of $52,664.56, on 07/16/2026.
The shares relate to restricted stock acquired from the issuer on 03/12/2021. During the past three months, Jayaraman sold 42,359 shares for $124,658.30 on 07/01/2026 and two blocks of 16,667 shares for $50,001.00 each on 05/29/2026 and 05/01/2026.
Cerus Corporation updated the employment terms for William “Obi” Greenman following his transition from President, Chief Executive Officer and Chairman to Executive Chairman effective July 1, 2026. Under an amendment to his employment letter, he will serve as Executive Chairman through May 31, 2027, with an anticipated time commitment averaging about 60% of a full-time schedule, unless earlier terminated or extended by written agreement. For this role, he will receive an annual base salary of $500,000 and, for 2026, will be eligible for an annual cash bonus with a target opportunity equal to 80% of his total 2026 base salary. He will not be entitled to earn an annual cash bonus for any portion of 2027. If his change in role triggers a qualifying event under the Consolidated Omnibus Reconciliation Act, Cerus will pay or reimburse his COBRA health insurance premiums, subject to his continued compliance with the amended letter agreement and his timely COBRA election. All other terms of the original letter agreement remain unchanged.
Cerus Corp Chief Financial Officer Kevin Dennis Green reported two stock transactions involving the company’s common shares. He sold 33,676 shares at a weighted average price of about $2.94 per share under a pre-set Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees tied to restricted stock unit vesting, which the footnote explains was not a discretionary sale.
On the same date, he also acquired 63,600 shares through a grant or award at no cost. Following these transactions, he directly holds 1,062,188 shares of Cerus common stock.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported a mix of equity grants and a tax-related share sale. He received 554,529 shares of common stock as an equity award and 369,686 performance rights, each tied to one share of common stock.
The common stock award vests in two annual installments, with 33% vesting on July 1, 2027 and 67% on July 1, 2028, contingent on continued service. The performance rights vest only if Cerus stock reaches a specified price per share.
On June 30, 2026, he sold 42,359 shares of common stock at a weighted average price of $2.9429 per share under a pre-set Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees, described as non-discretionary. After these transactions, he directly holds 2,248,877 common shares and 369,686 performance rights.
CERUS CORP Chief Legal Officer Chrystal Jensen reported two common stock transactions. On June 30, 2026, Jensen sold 24,329 shares of common stock at a weighted average price of $2.9429 per share. According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1 to cover statutory tax withholding obligations and related brokerage fees tied to vesting restricted stock units, and did not represent a discretionary sale.
On the same date, Jensen also acquired 55,000 shares of common stock as a grant or award at no cost. Following these transactions, Jensen directly held 966,657 shares of CERUS CORP common stock.
CERUS CORP President and CEO William Mariner Greenman reported a mix of tax-related sales and equity compensation grants in company stock. He sold 101,919 shares of common stock at a weighted average price of $2.94 per share under a pre-arranged Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees tied to vesting restricted stock units, which the disclosure notes was not a discretionary sale. He also received a grant or award of 192,500 shares of common stock at no cost. Following these transactions, he directly holds 5,053,036 shares of CERUS common stock.
Cerus Corp director Eric Bjerkholt sold shares in an open-market transaction. On this trade, he sold 20,454 shares of Cerus common stock at a price of $2.60 per share. After the sale, he directly owned 261,679 shares of the company’s common stock.